Navigation Links
Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to 'HRBR'
Date:2/17/2010

SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), today announced that it has changed its name to Harbor BioSciences, Inc. and that its ticker symbol will change from 'HEPH' to 'HRBR' on Thursday, February 18, 2010. The company also received a new CUSIP number (41150V 103) for its common stock.

"We are pleased to begin 2010 with a targeted business strategy focused on attaining proof-of-concept data for Apoptone® in its initial indication of CRPC," stated James Frincke, Ph.D., President and Chief Executive Officer. "Our new name, Harbor BioSciences, reflects our presence in the San Diego area and acknowledges the significant contributions of our dedicated employees here."  

Apoptone (HE3235) is a novel steroid analog of a dihydrotestosterone metabolite that has been found to stimulate cell death (apoptosis) in hormone-dependent prostate tumors.  Preliminary results of the company's ongoing Phase I/IIa clinical trial with Apoptone (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC) were presented on November 16, 2009 at the Molecular Targets and Cancer Therapeutics Conference.  These data will be updated later in Q1/2010.

About Harbor BioSciences, Inc.

Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone (HE3235), in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients.  The Triolex study will be completed in Q1/2010, with data expected in Q2/2010. Apoptone and Triolex represent the lead candidates from Harbor BioSciences small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones.  For more information on Harbor BioSciences please visit www.harborbiosciences.com.

This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, our receiving a new ticker symbol; our focus on attaining proof-of-concept data for Apoptone in its initial indication of CRPC; the update of the data from our ongoing Phase I/IIa clinical trial with Apoptone (HE3235) for CRPC; the completion of our Triolex study in Q1/2010; and availability of data from our Triolex study in Q2/2010.   Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause our actual results to differ materially from historical results or those expressed or implied by such forward-looking statements.  Such statements are subject to certain risks and uncertainties inherent in our business, including, but not limited to: the receipt of our new ticker symbol and the timing thereof; the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the availability of data within specified timelines; our capital needs; our ability to obtain additional funding; our ability to obtain regulatory approval for Apoptone (HE3235), Triolex (HE3286) or any other investigational drug candidate;  and other risks detailed from time to time in our filings with the Securities and Exchange Commission.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Except as required by law, we undertake no obligation to update or revise the information contained in this press release as a result of new information, future events or circumstances arising after the date of this press release.

SOURCE Harbor BioSciences, Inc.

RELATED LINKS
http://www.harborbiosciences.com

'/>"/>

SOURCE Harbor BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunridge Announces Marketing Roll Out of PNT in the Dominican Republic
2. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
3. Otix Global Announces Results for Fourth Quarter 2009
4. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
5. PatientSafe Solutions, Inc. Announces Management Team
6. Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test
7. CalciMedica Announces Issuance of US Patent No. 7,645,588, a Composition Patent Involving STIM1, a Key Component of the CRAC Channel
8. VetCentric Announces Partnership With Pfizer Animal Health
9. Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R)
10. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
11. Health Robotics Announces Successful Transition to new and Distinctively Superior Distribution Channels in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
Breaking Medicine News(10 mins):